Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.51 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7357350 | 1.00 | EPHX1 (0.58) | EPHX1SRRPSAT1TAAR1ANPEP | |
| SCHEMBL14733400 | 1.00 | EPHX1 (0.58) | EPHX1SRRPSAT1TAAR1ANPEP | |
| Hydrochloric Acid SCHEMBL30885862 | 0.98 | EPHX1 (0.56) | EPHX1SRRPSAT1TAAR1ANPEP | |
| Hydrochloric Acid SCHEMBL16932212 | 0.98 | EPHX1 (0.56) | EPHX1SRRPSAT1TAAR1ANPEP | |
| Hydrochloric Acid SCHEMBL16932213 | 0.98 | EPHX1 (0.56) | EPHX1SRRPSAT1TAAR1ANPEP | |
| Biphenyl SCHEMBL7890864 | 0.90 | EPHX1 (0.52) | EPHX1SRRPSAT1TAAR1ANPEP | |
| L-Phenylalaninol SCHEMBL81769 | 0.87 | EPHX1 (0.76) | EPHX1TAAR1ANPEPPTGS1 | |
| L-Phenylalaninol SCHEMBL2521 | 0.87 | EPHX1 (0.76) | EPHX1TAAR1ANPEPPTGS1 | |
| L-Phenylalaninol SCHEMBL87692 | 0.87 | EPHX1 (0.76) | EPHX1TAAR1ANPEPPTGS1 | |
| L-Phenylalaninol SCHEMBL177073 | 0.87 | EPHX1 (0.76) | EPHX1TAAR1ANPEPPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023206874-A1 | SACUBITRIL INTERMEDIATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 凯特立斯（深圳）科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| CN-116083497-A | Synthesis method of sakubi qu intermediate | 南通常佑药业科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116083497-A | Synthesis method of sakubi qu intermediate | 南通常佑药业科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-3558930-B1 | NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES | NOVARTIS AG (CH) | 2021-05-26 | — | — | EP | disclosed |
| US-10774036-B2 | Process for early sacubitril intermediates | NOVARTIS AG (CH) | 2020-09-15 | — | — | US | disclosed |
| US-20190256454-A1 | NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES | NOVARTIS PHARMA AG (CH) | 2019-08-22 | — | — | US | disclosed |
| EP-2890672-B1 | PROCESSES FOR PREPARING INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2018-05-30 | — | — | EP | disclosed |
| US-9624163-B2 | Process for preparing intermediates useful in the manufacture of NEP inhibitors | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9624163-B2 | Process for preparing intermediates useful in the manufacture of NEP inhibitors | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| CN-105026361-A | New process | ZHEJIANG JIUZHOU PHARM CO LTD | 2015-11-04 | — | — | CN | disclosed |
| US-20150210632-A1 | NEW PROCESS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210632-A1 | NEW PROCESS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| WO-2014032627-A1 | NEW PROCESS | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD (CN) | 2014-03-06 | — | — | WO | disclosed |
| US-6432933-B1 | MALARIA THERAPY; ALZHEIMER'S DISORDERS | PHARMACOPEIA, INC. | 2002-08-13 | — | — | US | disclosed |
| US-6326393-B1 | THERAPY FOR MALARIA, ALZHEIMER'S DISEASE | PHARMACOPEIA, INC. | 2001-12-04 | — | — | US | disclosed |
| US-6150344-A | USEFUL FOR TREATMENT OF DISEASES SUCH AS MALARIA AND ALZHEIMER'S DISEASE; COMPOUNDS ARE ATTACHED TO A SOLID SUPPORT | PHARMACOPEIA, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-5962506-A | THERAPY FOR ALZHEIMER'S DISEASE, MALARIA | PHARMACOPEIA, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999002153-A9 | GLYCOL AND HYDROXYPHOSPHONATE PEPTIDOMIMETICS AS INHIBITORS OF ASPARTYL PROTEASES | PHARMACOPEIA INC (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1999002153-A1 | GLYCOL AND HYDROXYPHOSPHONATE PEPTIDOMIMETICS AS INHIBITORS OF ASPARTYL PROTEASES | PHARMACOPEIA, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774036-B2 | Process for early sacubitril intermediates | MME, ACE, DNPEP | EPHX1 599/4885SRR 649/4885PSAT1 869/4885 |
| US-20150210632-A1 | NEW PROCESS | MME, DNPEP, ACE | EPHX1 76/4885SRR 694/4885PSAT1 1374/4885 |
| US-20190256454-A1 | NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES | MME, ACE, DNPEP | EPHX1 519/4885SRR 665/4885PSAT1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.